Kidney shield? diabetes drug tested to prevent ICU kidney failure
NCT ID NCT05468203
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether dapagliflozin, a drug used for diabetes and chronic kidney disease, could prevent acute kidney injury in critically ill patients in the intensive care unit (ICU). The trial planned to enroll 3,000 adults but was terminated early after only 51 participants. Patients were randomly assigned to receive either dapagliflozin or a placebo daily for up to 30 days while in the ICU.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Austin Health
Heidelberg, Victoria, 3084, Australia
-
Epworth Richmond
Richmond, Victoria, 3121, Australia
-
Grampians Health
Ballarat, Victoria, 3350, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which emergency dialysis saves more lives? a new study investigates
- A simple sensor on the back could warn of kidney danger during heart surgery
- Can a common blood thinner be safe for ICU patients with liver issues?
- A urine test that could foresee kidney danger in the ICU
- Which citrate solution minimizes metabolic chaos in kidney therapy?
- A wearable sensor might spot kidney danger before it strikes